Brisbane cancer drug developer Progen Industries (ASX:PGL) managing director Lewis Lee has resigned, and the company has named his replacement -- one-time Monsanto executive Justus Homburg.

Bioinformatics Australia, Australia's peak body for bioinformatics, hosted by industry organisation AusBiotech, has announced its newly elected committee.

Melbourne and California-based ChemGenex Pharmaceuticals (ASX:CXS) has been awarded two linkage project grants worth AUD$525,000 in cash from the Australian Research Council (ARC) over the next three years.

Susan Williamson discovers why the theme of tissue architecture is so prominent at this year's Lorne Cancer conference.

ASX debutant Dia-B Tech (ASX:DIA) suffered a poor debut today; although its shares listed at $0.27, they quickly fell below their $0.20 issue price and at time of writing were trading at $0.17.

ChemGenex Pharmaceuticals (ASX: CXS) has filed patent applications for another five novel depression-associated gene targets, bringing the total number of gene targets with patent protection from the CNS project to 10.

Deakin University molecular geneticist Professor Greg Collier was right on the mark when he chose the chubby Israeli sand rat as a model species for his quest for susceptibility genes for non insulin-dependent diabetes.

Can an extract of shark cartilage and crustacean shells alleviate the pain and inflammation of symptoms of osteoarthritis, the most common disease of aging? It’s a multi-billion question that medical science has shown little interest in answering, according to Melbourne rheumatologist and osteoarthritis expert Dr Daniel Lewis.

Can an extract of shark cartilage and crustacean shells alleviate the pain and inflammation of symptoms of osteoarthritis, the most common disease of aging?

A Melbourne research team's identification of an ancient family of transport proteins in yeast cells has revealed details of the symbiotic pact that led to the evolution of the first eukaryotic life forms some 2 billion years ago.

Melbourne drug-reengineering company Eiffel Technologies (ASX:EIF) says the results of a new pre-clinical study in an animal model confirm the early promise of insulin 'nanomised' by its proprietary supercritical fluid technology.